The fund marks the firm’s fourth dedicated life sciences fund, bringing its total assets under management as of Dec. 31 to $832 million.
Net IRRs of RiverVest Funds II and II are in the top 5% of all U.S. venture funds for their vintage years, as of Dec. 31, based on most-recent Cambridge Associates data.*
*As compared to the Cambridge Associates 2008 and 2014, respectively, U.S. HealthCare VC and All U.S. VC universes as of September 30, 2018; data were provided at no charge.